They also reported that knockdown of LLGL2 decreased cell surface levels of SLC7A5, and that knockdown of LLGL2 or SLC7A5 was sufficient to restore tamoxifen sensitivity to tamoxifen-resistant Erα-positive breast cancer cells under low leucine concentrations. This evidence concerns the gene LLGL2 and breast cancer.